Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc.BBOT · Entity 5215 | Director · President and CEO | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Oncology Therapeutics, Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,529 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Tax withholding · Disposed 1,047 · Balance 43,529 F1: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 20:12 UTC | BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215 | Tax withholdingCommon Stock | 1,047 | $3.94 | $4,125.18 |
DisclosureSEC source: 0001193125-26-414127 · ownership.xml · nonDerivative · entry 1 Beltran Pedro · CIK 0002058152 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,529 F1 · shares: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:00 UTC | BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215 | Tax withholdingCommon Stock | 1,047 | $7.80 | $8,166.60 |
DisclosureSEC source: 0001193125-26-296501 · ownership.xml · nonDerivative · entry 1 Beltran Pedro · CIK 0002058152 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,576 F1 · shares: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| May 10, 2026 Filed May 12, 2026 20:11 UTC | BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215 | GrantStock Option (Right to Buy) · Derivative | 1,103,837 | $0.00 Strike: $7.66 | $0.00 |
DisclosureSEC source: 0001193125-26-219439 · ownership.xml · derivative · entry 1 Beltran Pedro · CIK 0002058152 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,103,837 Underlying: Common Stock · 1,103,837 shares Expires 2036-05-09 F1 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 20, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| April 01, 2026 Filed May 5, 2026 23:03 UTC | BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215 | Tax withholdingCommon Stock | 1,047 | $9.03 | $9,454.41 |
DisclosureSEC source: 0001193125-26-207035 · ownership.xml · nonDerivative · entry 1 Beltran Pedro · CIK 0002058152 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,623 F1 · shares: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:57 UTC | BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215 | GrantStock Option (Right to Buy) · Derivative | 210,000 | $0.00 Strike: $10.19 | $0.00 |
DisclosureSEC source: 0001193125-26-104379 · ownership.xml · derivative · entry 2 Beltran Pedro · CIK 0002058152 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 210,000 shares Expires 2036-03-09 F2 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:57 UTC | BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215 | GrantCommon Stock | 46,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-104379 · ownership.xml · nonDerivative · entry 1 Beltran Pedro · CIK 0002058152 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,670 F1 · shares: Represents a grant of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 20:39 UTC | BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215 | GrantStock Option (Right to Buy) · Derivative | 357,177 | $0.00 Strike: $9.59 | $0.00 |
DisclosureSEC source: 0000950170-25-112003 · ownership.xml · derivative · entry 1 Beltran Pedro · CIK 0002058152 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 357,177 Underlying: Common Stock · 357,177 shares Expires 2035-08-25 F1 · derivative.exercise_date: A fraction of the shares underlying such option equal to (x) the number of full months between August 11, 2025 ("Vesting Commencement Date") and the date on which a registration statement on Form S-8 is filed and effective with the Securities and Exchange Commission (the "S-8 Filing Date") divided by (y) 48 shall vest on the S-8 Filing Date, and 1/48th of the shares underlying such option shall vest each month thereafter on the day of the month corresponding to the Vesting Commencement Date (and if there is no suchcorresponding day for a month, then the vesting date shall be the last day of the applicable month) until 100% of the shares underlying such option is vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.